Abstract:Donatella Delle Cave, 1, &ast Maria Mangini, 2, &ast Chiara Tramontano, 3, &ast Luca De Stefano, 3 Marco Corona, 1 Ilaria Rea, 3 Anna Chiara De Luca, 2 Enza Lonardo 1 1 National Research Council, Institute of Genetics and Biophysics, Naples, 80131, Italy; 2 National Research Council, Institute for Experimental Endocrinology and Oncology "G. Salvatore", Second Unit, Naples, 80131, Italy; 3 National Research Council, Institute of Applied Sciences and Intelligent Systems, Unit of Naples, Naples, 80131, Italy &astThese authors contributed equally to this work Correspondence: Ilaria Rea; Anna Chiara De Luca, Email ; Background: Metastasis-initiating cells are key players in progression, resistance, and relapse of colorectal cancer (CRC), by leveraging the regulatory relationship between Transforming Growth Factor-beta (TGF-β) signaling and anti-L1 cell adhesion molecule (L1CAM). Methods: This study introduces a novel strategy for CRC targeted therapy and imaging based on the use of a hybrid nanosystem made of gold nanoparticles-covered porous biosilica further modified with the (L1CAM) antibody. Results: The nanosystem intracellularly delivers galunisertib (LY), a TGF-β inhibitor, aiming to inhibit epithelial-mesenchymal transition (EMT), a process pivotal for metastasis. Anti-L1CAM antibody-functionalized nanoparticles (NPs) target tumor-initiating cells expressing L1CAM, inhibiting cancer growth. The number of antibody molecules conjugated to the single NP is precisely quantified, revealing a high surface coverage that facilitates the tumor targeting. The therapeutic efficacy of the nanosystem is investigated in organoid-like cultures of CRC cells and in vivo mouse models, showing a significant reduction in tumor growth. The spatial distribution of NPs within CRC tumors from mice is investigated using a label-free optical approach based on Raman micro-spectroscopy. Conclusion: This research highlights the multifunctional capabilities of engineered biosilica NPs, which offer new insights in targeted CRC therapy and imaging, improving patient outcomes and paving the way for personalized therapies. Keywords: targeted drug delivery, Raman imaging, antibody quantification, biosilica nanoparticle, in vivo treatment, colorectal cancer Metastasis continues to be the primary cause of mortality in colorectal cancer (CRC), 1 driven by the regenerative capacity of stem-like cells that initiate tumor growth at distant sites. 2 Despite significant advancements in managing localized disease, the prognosis for metastatic CRC remains poor, highlighting the urgent need for more effective therapeutic strategies. Chemotherapy, while a critical component of treatment, is often limited by drug resistance and systemic toxicity, 3 emphasizing the need for innovative approaches. Nanomedicine has emerged as a promising avenue in CRC treatment, 4 offering tailored interventions with enhanced efficacy and specificity compared to conventional methods. Engineered nanoparticles (NPs) fabricated from a variety of materials serve as versatile carriers capable of encapsulating therapeutic payloads while addressing the limitations of chemotherapy. 5,6 Active targeting strategies, which employ ligands on NP surfaces to target malignant cells, have shown potential to enhance drug delivery efficiency. 7 Among NPs, diatomite nanoparticles (DNPs) are noteworthy for their unique properties. Recent studies have demonstrated their versatility in biomedical applications, including CRC treatment. 8 Our study focuses on the development of hybrid nanosystems of DNPs and gold nanoparticles (AuNPs), embedded in gelatin (Gel), actively targeting metastatic CRC via L1CAM recognition and binding. These hybrid nanosystems provide a multifaceted approach to cancer therapy. They not only facilitate the delivery of therapeutic agents but also enable the visualization and sensing of drug distributions within tumor cells. By harnessing the unique properties of AuNPs, such as their plasmonic resonance, label-free Raman imaging can precisely map the distribution of both the nanoparticles and the drug within the tumor microenvironment. 9–11 This advanced imaging modality provides valuable insights into the pharmacokinetics and pharmacodynamics of the drug, facilitating a deeper understanding of its therapeutic efficacy. Moreover, acting as a protective shield for the drug payload, gelatin ensures the controlled drug release through its pH-dependent unfolding mechanism, protecting the drug payload from degradation and making the release trigger -Abstract Truncated-

Development, Optimization, and in vitro Evaluation of Silybin-loaded PLGA Nanoparticles and Decoration with 5TR1 Aptamer for Targeted Delivery to Colorectal Cancer Cells

Exploring the transformability of polymer-lipid hybrid nanoparticles and nanomaterial-biology interplay to facilitate tumor penetration, cellular uptake and intracellular targeting of anticancer drugs

Anticancer Potential of Silibinin Loaded Polymeric Nanoparticles against Breast Cancer Cells: Insight into the Apoptotic Genes Targets

Synthesis, Characterization, and In-Vitro Evaluation of Silibinin-loaded PEGylated Niosomal Nanoparticles: Potential Anti-Cancer Effects on SW480 Colon Cancer Cells

Silibinin-Loaded Amphiphilic PLGA–Poloxamer Nanoparticles: Physicochemical Characterization, Release Kinetics, and Bioactivity Evaluation in Lung Cancer Cells

Enhancement of in-vitro anti-oral cancer activities of silymarin using dispersion of nanostructured lipid carrier in mucoadhesive in-situ gel

Oral delivery of solid lipid nanoparticles surface decorated with hyaluronic acid and bovine serum albumin: A novel approach to treat colon cancer through active targeting

Fabrication of anionic dextran-coated micelles for aptamer targeted delivery of camptothecin and survivin-shRNA to colon adenocarcinoma

Enhanced theranostic efficacy of epirubicin-loaded SPION@MSN through co-delivery of an anti-miR-21 expressing plasmid and ZIF-8 hybridization to target colon adenocarcinoma

The silibinin-loaded Zein-β cyclodextrin nano-carriers (SZBC-NCs) as a novel selective cancer cell drug delivery system in HT-29 cell line

Engineered PLGA Core-Lipid Shell Hybrid Nanocarriers Improve the Efficacy and Safety of Irinotecan to Combat Colon Cancer

Multifunctional Tumor-Targeted PLGA Nanoparticles Delivering Pt(IV)/siBIRC5 for US/MRI Imaging and Overcoming Ovarian Cancer Resistance.

Synthesis of novel polymeric nanoparticles (methoxy-polyethylene glycol-chitosan/hyaluronic acid) containing 7-ethyl-10-hydroxycamptothecin for colon cancer therapy: in vitro, ex vivo and in vivo investigation

Mesoporous Silica Nanoparticles-based Smart Nanocarriers for Targeted Drug Delivery in Colorectal Cancer Therapy

Surface modification of hollow gold nanoparticles conducted by incorporating cancer cell membrane and AS1411 aptamer, aiming to achieve a dual-targeted therapy for colorectal cancer

Good's Buffer Based Highly Biocompatible Ionic Liquid Modified PLGA Nanoparticles for the Selective Uptake in Cancer Cells

Dual-drug loaded nanoformulation with a galactosamine homing moiety for liver-targeted anticancer therapy.

Hybrid Biosilica Nanoparticles for in-vivo Targeted Inhibition of Colorectal Cancer Growth and Label-Free Imaging

Real-Time Label-Free Targeting Assessment and in Vitro Characterization of Curcumin-Loaded Poly-lactic- co-glycolic Acid Nanoparticles for Oral Colon Targeting

Nucleolin-targeted cationic nanoparticle for delivery of survivin shRNA against colorectal cancer in vitro and in vivo

Comparison of cell delivery and cell membrane camouflaged PLGA nanoparticles in the delivery of shikonin for colorectal cancer treatment